A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
复制标题
通过免疫化学疗法治疗的弥漫性大B细胞淋巴瘤患者的改良预后模型。
DOI：
10.3892/ol.2021.12479
复制
发表时间：
2021-03
期刊：
影响因子：
2.9
通讯作者：
Zhang H
中科院分区：
文献类型：
--
作者：
Zhao P;Zhu L;Li L;Zhou S;Qiu L;Qian Z;Xu W;Zhang H
In the era of immunochemotherapy, the traditional international prognostic index (IPI) has partially lost its predictive value in diffuse large B-cell lymphoma (DLBCL) and the National Comprehensive Cancer Network-IPI (NCCN-IPI) is unable to effectively identify high-risk patients. Thus, the present study aimed to develop a modified prognostic model (M-PM) to identify high-risk patients that require aggressive treatment. The present study included 169 patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP) or RCHOP-like regimens, between 2011–2017. The results demonstrated that the risk discrimination was improved in the NCCN-IPI compared with the IPI, and patients were divided into four risk groups with a 5-year overall survival rate of 93.8, 76.5, 54.3 and 39.4%, respectively. However, the NCCN-IPI failed to identify the high-risk DLBCL population. The newly developed M-PM presented here included four parameters: Age (≥65 years), an elevated lactate dehydrogenase level, Eastern Cooperative Oncology Group score ≥2 and total metabolic tumor volume ≥300 cm3. The M-PM also divided patients into four risk groups that comprised 40.8, 23.1, 26.0 and 10.1% of the patients, and the 5-year survival rates of these groups were 92.4, 70.6, 52.3 and 24.5%, respectively. Taken together, the results of the present study demonstrated that the M-PM was more accurate compared with the IPI and the NCCN-IPI, which served as an effective tool for identifying patients with DLBCL at high risk of an adverse prognosis.
登录
查看更多内容
DOI：
10.1007/s00259-011-1758-4
发表时间：
2011-07-01
影响因子：
9.1
作者：
Gulec, Seza A.;Suthar, Rekha R.;Pennington, Kenneth
通讯作者：
Pennington, Kenneth
影响因子：
50.5
作者：
Bari, A.;Marcheselli, L.;Cox, M. C.
通讯作者：
Cox, M. C.
影响因子：
6.5
作者：
Montalban, Carlos;Diaz-Lopez, Antonio;Garcia, Juan F.
通讯作者：
Garcia, Juan F.
影响因子：
6.2
作者：
Kim, Tae Min;Paeng, Jin Chul;Heo, Dae Seog
通讯作者：
Heo, Dae Seog
影响因子：
82.9
作者：
Chapuy B;Stewart C;Dunford AJ;Kim J;Kamburov A;Redd RA;Lawrence MS;Roemer MGM;Li AJ;Ziepert M;Staiger AM;Wala JA;Ducar MD;Leshchiner I;Rheinbay E;Taylor-Weiner A;Coughlin CA;Hess JM;Pedamallu CS;Livitz D;Rosebrock D;Rosenberg M;Tracy AA;Horn H;van Hummelen P;Feldman AL;Link BK;Novak AJ;Cerhan JR;Habermann TM;Siebert R;Rosenwald A;Thorner AR;Meyerson ML;Golub TR;Beroukhim R;Wulf GG;Ott G;Rodig SJ;Monti S;Neuberg DS;Loeffler M;Pfreundschuh M;Trümper L;Getz G;Shipp MA
通讯作者：
Shipp MA